IMF: Australia may need further rate hikes - Breaking The News
Download our appPlay StoreApp Store

IMF: Australia may need further rate hikes

EPA-EFE/MICK TSIKAS

The International Monetary Fund (IMF) said in its report on Australia that the country's central bank may need to raise interest rates further this year in order to bring inflation down to its target.

The report noted that IMF executive directors "highlighted the potential need for further monetary tightening to achieve the targeted inflation range by 2025 and recommended a data‑dependent approach." The directors also commended Australia's "progress on fiscal consolidation and commitment to debt sustainability" but stressed the need for "a tighter fiscal stance."

The Reserve Bank of Australia (RBA) raised interest rates multiple times in 2023, bringing its key rate to 4.35%, but decided to hold rates at its last meeting.

Related News
J&J, Merck CEOs to testify before Senate on drug prices
United States Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP) Bernie Sanders announced in a statement that CEOs from Johnson & Johnson and Merck & Co. Inc. will be joining Bristol Myers Squibb Co. CEO Chris Boerner at a hearing related to "outrageously high price of prescription drugs" in the country. "Let me thank the CEOs of Johnson & Johnson and Merck for agreeing to join the CEO of Bristol Myers Squibb and...
Bristol-Myers to acquire Karuna Therapeutics for $14B
Bristol-Myers Squibb Company will acquire Boston-based biotech company Karuna Therapeutics for $14 billion, The Wall Street Journal reported on Friday. The pharmaceutical giant based in Princeton is anticipated to make a cash payment of $330 per share for Karuna, including its experimental schizophrenia medicine currently awaiting approval from the Food and Drug Administration (FDA). The transaction is expected to be finalized in the first half...
Bristol-Myers Squibb to acquire Mirati for $4.8B
Bristol-Myers Squibb Company announced it will acquire Mirati Therapeutics Inc. for $58 per share in cash in a transaction that will amount to $4.8 billion. The deal is expected to clear the regulatory process and to be finalized by the first half of 2024. "Mirati is a commercial stage targeted oncology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. Mirati's assets...
Bristol-Myers Squibb to buy MyoKardia for $13.1B
Bristol-Myers Squibb announced on Monday it will acquire MyoKardia Inc in an all-cash deal worth $13.1 billion, or $225 a share. MyoKardia specializes in heart treatment and its experimental drug code-named mavacamten, which treats a chronic heart condition called hypertrophic cardiomyopathy. Bristol-Myers Squibb CEO Giovanni Caforio noted the company is planning to seek regulatory approval for the drug next year and noted...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.